1
Clinical Trials associated with Vascular endothelial growth factor-121 localised protein delivery(GenVec, Inc.)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA™-GUIDED/MYOSTAR™ Catheter in "No Option" Patients With Class II-IV Stable Angina
The primary purpose of this study is to determine whether treatment with an experimental gene therapy (BIOBYPASS®) will reduce angina in study participants by stimulating the growth of new blood vessels. This will be measured by testing whether participants are able to exercise longer without experiencing angina after treatment, as compared to before treatment.
Additionally, this study will collect information about any side effects that might be related to the treatment with the experimental therapy.
100 Clinical Results associated with Vascular endothelial growth factor-121 localised protein delivery(GenVec, Inc.)
100 Translational Medicine associated with Vascular endothelial growth factor-121 localised protein delivery(GenVec, Inc.)
100 Patents (Medical) associated with Vascular endothelial growth factor-121 localised protein delivery(GenVec, Inc.)
100 Deals associated with Vascular endothelial growth factor-121 localised protein delivery(GenVec, Inc.)